FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHA	NGES IN	BENEFICIAL

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									
hours per response:										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Biller Jonathan</u>															k all applic Directo	or (give title		son(s) to Issuer 10% Owner Other (specify below)	
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET			02/1	3. Date of Earliest Transaction (Month/Day/Year) 02/18/2022									Chief Financial Officer						
(Street) CAMBRII (City)	DGE MA		2139 Zip)		4. If i	4. If Amendment, Date of Original Filed (Month/Day/Year)									ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tabl	e I - No	n-Deriv	ative	Sec	uriti	es Acc	quired,	Dis	posed o	f, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3)		Date	Date E (Month/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			and 5) Securitie Benefici		s ally following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) o (D)	Pric	е	Transact (Instr. 3 a	ion(s)			(11150.4)	
Common stock			02/18	3/2022				М		8,523	A		50	25,641			D		
Common stock 02.			02/22	/2022			F		2,688	D	\$2	29.08		22,953		D			
		Ta									osed of, onvertib				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	Date, Transact				6. Date Exercisal Expiration Date (Month/Day/Year		Amount of Securities Underlying Derivative Securities (Instr. 3 and 4)		of es ng re Secur and 4)	ity	8. Price of Derivative Security Instr. 5)		e Owi s Form lily Dire or li (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amou or Numl of Share	oer					
Performance share units	(1)	02/18/2022			М			8,523	(2)		(2)	Commor	8,52	23	\$0	8,522	2	D	

Explanation of Responses:

- 1. Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Remarks:

/s/ William Cook, as Attorney in Fact for Jonathan Biller

OWNERSHIP

02/23/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.